ATE178939T1 - DNA METHYLTRANSFERASE INHIBITION - Google Patents

DNA METHYLTRANSFERASE INHIBITION

Info

Publication number
ATE178939T1
ATE178939T1 AT95901306T AT95901306T ATE178939T1 AT E178939 T1 ATE178939 T1 AT E178939T1 AT 95901306 T AT95901306 T AT 95901306T AT 95901306 T AT95901306 T AT 95901306T AT E178939 T1 ATE178939 T1 AT E178939T1
Authority
AT
Austria
Prior art keywords
cell
demethylase
dna
level
dna methyltransferase
Prior art date
Application number
AT95901306T
Other languages
German (de)
Inventor
Moshe Szyf
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002110213A external-priority patent/CA2110213A1/en
Priority claimed from GB9413680A external-priority patent/GB9413680D0/en
Application filed by Univ Mcgill filed Critical Univ Mcgill
Application granted granted Critical
Publication of ATE178939T1 publication Critical patent/ATE178939T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Abstract

The present invention relates to the interplay between the level of DNA methyltransferase and demethylase activities, to the role of the interplay between these levels on the proliferative, differentiated, tumorigenic and homeostatic state of the cell, and to the DNA methyltransferase and demethylase as therapeutic targets. The invention further relates to a reduction of the level of DNA methylation through inhibitors and antagonist in order to inhibit the excessive activity or hypermethylation of DNA MeTase in cancer cells to induce the original cellular tumor suppressing program, to turn on alternative gene expression programs, to provide therapeutics directed at a nodal point of regulation of genetic information, and to modulate the general level of methylase and demethylase enzymatic activity of a cell to permit specific changes in the methylation pattern of a cell (Fig. 1). <IMAGE>
AT95901306T 1993-11-30 1994-11-30 DNA METHYLTRANSFERASE INHIBITION ATE178939T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002110213A CA2110213A1 (en) 1993-11-30 1993-11-30 Inhibition of dna metase for therapy
GB9413680A GB9413680D0 (en) 1994-07-07 1994-07-07 Inhibition of tumorgenicity by inhibiting DNA methyltransferase activity

Publications (1)

Publication Number Publication Date
ATE178939T1 true ATE178939T1 (en) 1999-04-15

Family

ID=25676818

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95901306T ATE178939T1 (en) 1993-11-30 1994-11-30 DNA METHYLTRANSFERASE INHIBITION

Country Status (9)

Country Link
US (1) US6184211B1 (en)
EP (3) EP0889122A3 (en)
JP (1) JPH09506253A (en)
KR (1) KR100392057B1 (en)
AT (1) ATE178939T1 (en)
AU (1) AU1061395A (en)
CA (1) CA2177031A1 (en)
DE (1) DE69417918T2 (en)
WO (1) WO1995015373A2 (en)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652105A (en) * 1995-07-28 1997-07-29 Health Research, Inc. Substrate for detection of mammalian 5-C-DNA methyltransferase
WO1997044346A2 (en) * 1996-05-22 1997-11-27 Mcgill University Specific inhibitors of dna methyltransferase enzyme
US6268137B1 (en) 1996-05-22 2001-07-31 Methylgene, Inc. Specific inhibitors of DNA methyl transferase
US7138384B1 (en) 1997-08-29 2006-11-21 The Regents Of The University Of California Modulators of DNA cytosine-5 methyltransferase and methods for use thereof
AU1138699A (en) * 1997-11-12 1999-05-31 Mcgill University Dna demethylase, therapeutic and diagnostic uses thereof
DE19754482A1 (en) * 1997-11-27 1999-07-01 Epigenomics Gmbh Process for making complex DNA methylation fingerprints
US7026155B2 (en) * 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
CA2291367A1 (en) * 1999-12-06 2001-06-06 Isabelle Henry Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
DE10010282B4 (en) 2000-02-25 2006-11-16 Epigenomics Ag Method for the detection of cytosine methylation in DNA samples
EP1370685A2 (en) 2000-04-06 2003-12-17 Epigenomics AG Diagnosis of diseases associated with dna repair
WO2003006987A1 (en) * 2000-12-11 2003-01-23 The Salk Institute For Biological Studies Methods and compositions for determining enzymatic activity and specificity of methyltransferases
WO2002101353A2 (en) * 2001-06-08 2002-12-19 U.S. Genomics, Inc. Methods and products for analyzing nucleic acids based on methylation status
AU2002322805B2 (en) * 2001-07-31 2007-11-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitor of DNA methylation
DE10154317B4 (en) 2001-10-26 2005-06-09 Epigenomics Ag Method for the detection of cytosine methylations in immobilized DNA samples
EP1340818A1 (en) 2002-02-27 2003-09-03 Epigenomics AG Method and nucleic acids for the analysis of a colon cell proliferative disorder
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
WO2005059172A2 (en) 2003-12-11 2005-06-30 Epigenomics Ag Method and nucleic acids for the improved treatment of breast cell proliferative disorders
CA2500255A1 (en) 2002-10-01 2004-04-29 Epigenomics Ag Method and nucleic acids for the treatment of breast cell proliferative disorders
AU2003295444A1 (en) * 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
AU2003902704A0 (en) * 2003-05-29 2003-06-19 Crc For Waste Management And Pollution Control Limited Of Unsw Process for producing a nanoscale zero-valent metal
EP1636386B1 (en) 2003-06-23 2015-08-05 Epigenomics AG Methods and nucleic acids for analyses of colorectal cell proliferative disorders
EP2354249A1 (en) 2003-06-23 2011-08-10 Epigenomics AG Methods and nucleic acids for analyses of colorectal cell proliferative disorders
ATE494390T1 (en) 2003-06-23 2011-01-15 Epigenomics Ag METHOD AND NUCLEIC ACIDS FOR ANALYZING DISORDERS IN COLON CELL PROLIFERATION
WO2005012575A1 (en) * 2003-08-01 2005-02-10 U.S. Genomics, Inc. Methods and compositions related to the use of sequence-specific endonucleases for analyzing nucleic acids under non-cleaving conditions
AU2004295712B2 (en) 2003-12-01 2011-05-19 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
EP1778865A1 (en) 2004-06-23 2007-05-02 Epigenomics AG Methods and nucleic acids for the detection of metastasis of colon cell proliferative disorders
US20090298054A1 (en) 2004-07-18 2009-12-03 Epigenomics Ag Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders
EP2311984A1 (en) 2004-12-02 2011-04-20 Epigenomics AG Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2006107751A2 (en) * 2005-04-01 2006-10-12 Methylgene, Inc. Combined therapy utilizing reduction of dna methyltansferase expression and/or activity and interferon
SG183708A1 (en) 2005-04-15 2012-09-27 Epigenomics Ag Methods and nucleic acids for analyses of cellular proliferative disorders
EP1885884A2 (en) 2005-05-02 2008-02-13 University Of Southern California DNA METHYLATION MARKERS ASSOCIATED WITH THE CpG ISLAND METHYLATOR PHENOTYPE (CIMP) IN HUMAN COLORECTAL CANCER
ES2623221T3 (en) * 2005-05-20 2017-07-10 Methylgene Inc VEGF receptor and HGF receptor signaling inhibitors
US20090191548A1 (en) 2005-09-29 2009-07-30 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with tissue classification
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN101437933B (en) 2005-12-28 2013-11-06 斯克里普斯研究所 Natural antisense and non-coding RNA transcripts as drug targets
AR060061A1 (en) * 2006-03-22 2008-05-21 Methylgene Inc INHIBITORS OF THE ACTIVITY OF PROTEIN TIROSINA QUINASA
WO2007118704A2 (en) 2006-04-17 2007-10-25 Epigenomics Ag Methods and nucleic acids for the detection of colorectal cell proliferative disorders
WO2008035209A2 (en) * 2006-05-30 2008-03-27 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
EP2634265B1 (en) 2006-07-21 2016-09-14 Epigenomics AG Methods related to the gene GLI3 for detection of colorectal cancer
US20080255155A1 (en) * 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
US20100203514A1 (en) 2006-11-24 2010-08-12 Sledziewski Andrew Z Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders
CA2675895C (en) 2007-01-19 2016-03-22 Epigenomics Ag Methods and nucleic acids for analyses of cell proliferative disorders
EP2302069A1 (en) 2007-12-11 2011-03-30 Epigenomics AG Methods and nucleic acids for analyses of cell proliferative disorders
US8293897B2 (en) 2008-10-14 2012-10-23 Ning Xi Compounds comprising a spiro-ring and methods of use
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
US20110294870A1 (en) 2008-12-04 2011-12-01 Opko Curna, Llc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
ES2629630T3 (en) 2008-12-04 2017-08-11 Curna, Inc. Treatment of diseases related to erythropoietin (EPO) by inhibiting the natural antisense transcript to EPO
ES2762610T3 (en) 2009-02-12 2020-05-25 Curna Inc Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of natural antisense transcript for BDNF
MX2011009751A (en) 2009-03-16 2011-09-29 Opko Curna Llc Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2.
WO2010107740A2 (en) 2009-03-17 2010-09-23 Curna, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
JP6250930B2 (en) 2009-05-06 2017-12-20 クルナ・インコーポレーテッド Treatment of TTP-related diseases by suppression of natural antisense transcripts against tristetraproline (TTP)
CN102459596B (en) 2009-05-06 2016-09-07 库尔纳公司 By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
KR101742334B1 (en) 2009-05-08 2017-06-01 큐알엔에이, 인크. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
CN102575251B (en) 2009-05-18 2018-12-04 库尔纳公司 The relevant disease of the reprogramming factor is treated by inhibiting the natural antisense transcript for the reprogramming factor
KR101703695B1 (en) 2009-05-22 2017-02-08 큐알엔에이, 인크. Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
CN103221541B (en) 2009-05-28 2017-03-01 库尔纳公司 Antiviral gene relevant disease is treated by the natural antisense transcript suppressing antiviral gene
KR101702689B1 (en) 2009-06-16 2017-02-06 큐알엔에이, 인크. Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
AR077238A1 (en) 2009-06-26 2011-08-10 Unilever Nv COMPOSITIONS FOR ORAL CARE. USE OF A POLYMER TO MANUFACTURE THE COMPOSITION
CA2768947C (en) 2009-07-24 2018-06-19 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
US9234199B2 (en) 2009-08-05 2016-01-12 Curna, Inc. Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS)
EP2464731B1 (en) 2009-08-11 2016-10-05 CuRNA, Inc. Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
CN102482671B (en) 2009-08-25 2017-12-01 库尔纳公司 IQGAP relevant diseases are treated by suppressing the natural antisense transcript of ' gtpase activating protein containing IQ die bodys ' (IQGAP)
EP2480669B1 (en) 2009-09-25 2017-11-08 CuRNA, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
US20110104695A1 (en) 2009-11-05 2011-05-05 Epigenomics Ag Methods of predicting therapeutic efficacy of cancer therapy
ES2661813T3 (en) 2009-12-16 2018-04-04 Curna, Inc. Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene
US9068183B2 (en) 2009-12-23 2015-06-30 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
CA2782373C (en) 2009-12-23 2019-03-26 Opko Curna, Llc Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
WO2011090740A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
ES2585829T3 (en) 2009-12-29 2016-10-10 Curna, Inc. Treatment of diseases related to tumor protein 63 (p63) by inhibition of natural antisense transcription to p63
US20120289583A1 (en) 2009-12-31 2012-11-15 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
KR101878501B1 (en) 2010-01-04 2018-08-07 큐알엔에이, 인크. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
EP2521785B1 (en) 2010-01-06 2022-03-09 CuRNA, Inc. Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
CN102782135A (en) 2010-01-25 2012-11-14 库尔纳公司 Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1
CN102844435B (en) 2010-02-22 2017-05-10 库尔纳公司 Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
ES2657969T3 (en) 2010-04-02 2018-03-07 Curna, Inc. Treatment of diseases related to Colony Stimulating Factor 3 (CSF3) by inhibition of the natural antisense transcript to CSF3
RU2610661C2 (en) 2010-04-09 2017-02-14 Курна, Инк. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
CN107988228B (en) 2010-05-03 2022-01-25 库尔纳公司 Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to Sirtuin (SIRT)
TWI531370B (en) 2010-05-14 2016-05-01 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
CA2799596C (en) 2010-05-26 2020-09-22 Curna, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
KR102008708B1 (en) 2010-06-23 2019-08-08 큐알엔에이, 인크. Treatment of sodium channel voltage-gated, alpha subunit (scna) related diseases by inhibition of natural abtisense transcript to scna
CN103068982B (en) 2010-07-14 2017-06-09 库尔纳公司 DLG relevant diseases are treated by suppressing the natural antisense transcript of the big homologue of plate-like (DLG)
EP2625274B1 (en) 2010-10-06 2017-07-19 CuRNA, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
CA2815212A1 (en) 2010-10-22 2012-04-26 Curna, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
CN103459599B (en) 2010-11-23 2017-06-16 库尔纳公司 NANOG relevant diseases are treated by suppressing the natural antisense transcript of NANOG
RU2568258C2 (en) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Substituted quinoline compounds and methods of their application
JP6188686B2 (en) 2011-06-09 2017-08-30 カッパーアールエヌエー，インコーポレイテッド Treatment of FXN-related diseases by inhibition of natural antisense transcripts to frataxin (FXN)
MX358117B (en) 2011-07-08 2018-08-06 Epigenomics Ag Methods and nucleic acids for determining the prognosis of a cancer subject.
AU2012302051B2 (en) 2011-08-30 2017-04-27 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
CA2847811C (en) 2011-09-06 2019-10-22 Curna, Inc. Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules
US20150031750A1 (en) 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
AU2013296897B2 (en) 2012-07-28 2015-09-17 Beijing Findcure Biosciences Ltd. Substituted pyrazolone compounds and methods of use
TWI574962B (en) 2012-11-14 2017-03-21 加拓科學公司 Heteroaromatic compounds as pi3 kinase modulators and methods of use
SG11201505493QA (en) 2013-02-21 2015-08-28 Calitor Sciences Llc Heteroaromatic compounds as pi3 kinase modulators
EP2971169A4 (en) 2013-03-13 2016-10-26 Abbott Molecular Inc Systems and methods for isolating nucleic acids
EP2971171A4 (en) 2013-03-14 2016-11-02 Abbott Molecular Inc Multiplex methylation-specific amplification systems and methods
CA2902916C (en) 2013-03-14 2018-08-28 Mayo Foundation For Medical Education And Research Detecting neoplasm
WO2015124921A1 (en) 2014-02-19 2015-08-27 The University Court Of The University Of Edinburgh Methods and uses for determining the presence of inflammatory bowel disease
EP3126519A4 (en) 2014-03-31 2018-01-17 Mayo Foundation for Medical Education and Research Detecting colorectal neoplasm
US10465248B2 (en) 2014-12-12 2019-11-05 Exact Sciences Development Company, Llc Method of characterizing ZDHHC1 DNA
US10435755B2 (en) 2015-03-27 2019-10-08 Exact Sciences Development Company, Llc Detecting esophageal disorders
EP3316685A4 (en) 2015-07-02 2019-03-13 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
KR102627044B1 (en) 2015-10-19 2024-01-18 선샤인 레이크 파르마 컴퍼니 리미티드 Salts of EGFR inhibitors, their crystalline forms and uses
US10822638B2 (en) 2015-10-30 2020-11-03 Exact Sciences Development Company, Llc Isolation and detection of DNA from plasma
KR20170050916A (en) * 2015-11-02 2017-05-11 연세대학교 산학협력단 Method for controlling differentiatin of stem cell by epigenetic modification of intragenic cpg island
US10385406B2 (en) 2016-05-05 2019-08-20 Exact Sciences Development Company, Llc Detection of lung neoplasia by analysis of methylated DNA
EP3488004B1 (en) 2016-07-19 2021-10-06 Exact Sciences Development Company, LLC Methylated control dna
KR20240038151A (en) 2016-09-02 2024-03-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Detecting hepatocellular carcinoma
US11118228B2 (en) 2017-01-27 2021-09-14 Exact Sciences Development Company, Llc Detection of colon neoplasia by analysis of methylated DNA
WO2019025863A2 (en) 2017-08-03 2019-02-07 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
EP3880847A2 (en) 2018-11-16 2021-09-22 Oslo Universitetssykehus HF Methods and compositions for characterizing bladder cancer
CN111321210B (en) * 2018-12-13 2021-09-14 贵阳优乐复生医学检验所有限公司 Method for non-invasive prenatal detection of whether fetus suffers from genetic disease
CA3154354A1 (en) 2019-10-31 2021-05-06 William R. Taylor Detecting ovarian cancer
WO2022040306A1 (en) 2020-08-19 2022-02-24 Mayo Foundation For Medical Education And Research Detecting non-hodgkin lymphoma
WO2022165247A1 (en) 2021-01-29 2022-08-04 Mayo Foundation For Medical Education And Research Detecting the presence or absence of multiple types of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006985A1 (en) * 1990-10-23 1992-04-30 City Of Hope Mechanism based inhibitors of dna methyltransferase
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6020318A (en) * 1997-05-30 2000-02-01 Methylgene, Inc. DNA methyltransferase genomic sequences and antisense oligonucleotides

Also Published As

Publication number Publication date
WO1995015373A3 (en) 1995-08-10
WO1995015373A2 (en) 1995-06-08
EP0734436B1 (en) 1999-04-14
EP1352956A1 (en) 2003-10-15
US6184211B1 (en) 2001-02-06
EP0889122A2 (en) 1999-01-07
KR100392057B1 (en) 2003-10-30
AU1061395A (en) 1995-06-19
CA2177031A1 (en) 1995-06-08
DE69417918D1 (en) 1999-05-20
DE69417918T2 (en) 2000-01-05
EP0889122A3 (en) 1999-03-03
EP0734436A1 (en) 1996-10-02
JPH09506253A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
ATE178939T1 (en) DNA METHYLTRANSFERASE INHIBITION
PT1201639E (en) Lipoxin compounds and their use in treating cell proliferative disorders
BR0010220A (en) Pyrimidinone compounds
DE69512036D1 (en) ANALOGS OF BENZAMIDE, FOR USE AS PARP (ADP-RIBOSYL TRANSFERASE, ADPRT) DNA REPAIR CYCLE INHIBITORS
DK1280552T3 (en) A method of treating skin cancer using compositions comprising an endothelin B receptor inhibitor
DK1233958T3 (en) Inhibitors of histone deacetylase
DK0998568T3 (en) Mutant with uracil phosphoribosyl transferase activity
BR9916735A (en) 3-Heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
EP0981607A4 (en) Modiified arginine deiminase
NO20002127D0 (en) Therapeutically active compounds based on indazole-bioster replacement of catechol in PDE4 inhibitors
AU2001247704A1 (en) Methods and computer readable medium for improved radiotherapy dosimetry planning
ZA993777B (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
EP1180932A4 (en) Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
HK1028350A1 (en) Leptin as an inhibitor of tumor cell proliferation.
AU8742198A (en) Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
ATE341639T1 (en) ADENOVIRUS-MEDIATED GENE THERAPY
NO954880L (en) Cytidine deaminase
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
PT1002095E (en) IMPROVED STRANDS FOR PROTEIN EXPRESSION
PL353035A1 (en) Use of fviia or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
EP1018003A4 (en) Modulators of dna cytosine-5 methyltransferase and methods for use thereof
Bases et al. Enhanced repair endonuclease activities from radiation-arrested G2 phase mammalian cells
SE0302965D0 (en) Inhibitors of DNA methyltransferase isoforms
WO2001079526A3 (en) Live cell procedures to identify compounds modulating intracellular distribution of phosphodiesterase (pde) enzymes
NZ506005A (en) Recombinant proteins derived from hgf and msp

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties